ReviewAdvances in radiation oncology2025
The Burden of Insurance Prior Authorization on Cancer Care: A Review of Evidence From Radiation Oncology.
Review in Advances in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Radiation Therapy Infrastructure, Social Vulnerability, and Insurance Architecture Predict Timely Postoperative Radiation Therapy After Brain Tumor Craniotomy.Advances in radiation oncology · 2026Article
- Examination of insurance type and cancer treatments with administrative burdens and financial toxicity in a sample of cancer survivors.Journal of cancer survivorship : research and practice · 2026Article
- Inpatient and Postacute Care After Head and Neck Surgery Among Beneficiaries.Laryngoscope investigative otolaryngology · 2026Article
- Second-Level Appeals of Denied Anticancer Medication Claims in Medicare Part D.JAMA network open · 2026Article
- Caregiver experiences of healthcare-related administrative burden: a scoping review.Health affairs scholar · 2026Review
- Evaluating time to access opioid treatment for patients with insurance that requires the Safe & Effective Management of Pain prior authorization form vs others.Journal of managed care & specialty pharmacy · 2025Article
- County-level medical debt and treatment initiation among individuals newly diagnosed with cancer.Cancer · 2025Article
- Advances in Therapeutics for Chronic Lung Diseases: From Standard Therapies to Emerging Breakthroughs.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Despite its high cost-effectiveness, radiation oncology faces the greatest prior authorization (PA) burden of any medical specialty. Insurance denials and resulting treatment delays have been documented across several treatment modalities, including stereotactic body radiation, intensity modulated radiation, and proton therapy. Although insurance companies suggest that PA is intended to control health care spending and ensure the implementation of evidence-based practice, the number of radiation treatment plans reviewed by the PA process that result in changes is quite low. Yet, the cost to patients, providers, and the health care system is rising.The increased administrative work required to address the appeal process, including the development of radiation plan comparisons, results in lost productivity of radiation staff and increased clinic costs that are not currently reimbursed. Treatment delays from PA may elevate patient anxiety and affect their ability to enroll in clinical trials, resulting in decreased quality of care. As a result of possible harm to patients, the Centers for Medicare and Medicaid Services developed a ruling that mandates increased transparency of insurers' requirements, decreased allowable time for arriving at PA decisions, and a more efficient electronic communication system to address the time and resource burden of PA. Methods and Materials: This article summarizes key discussions from the literature and provides recommendations to help mitigate insurance PA strain. Results: These recommendations broadly address the following key areas: (1) omission of PA for routine care and clinical trials, (2) implementation of efficient, streamlined electronic peer-to-peer communication, (3) increased transparency of insurance requirements and rationale for denials, and (4) decreased time allowances for PA decisions. Conclusions: Policy reform focused on evidence-driven treatment coverage, reduction of the proportion of cases requiring PA, and a simplified, timely insurance appeal process is necessary to ensure optimal cancer care for patients requiring radiation therapy as part of their cancer journey.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.